The liver is the largest organ in the human body and it situated in the right upper quarter of the abdominal cavity just under the right lower ribs. It extends from the right nipple to the costal margin (the lower border of the rib cage).  A large part of the liver is protected by the right lower ribs.

Approximately a quarter of the blood of the body flows through the liver every minute. Like all other major organs in the body the liver receives a direct arterial blood supply via the hepatic artery. However, in addition the liver has a second (dual) venous blood supply in that the blood that leaves the intestines (bowels) also flows through the portal vein and into the liver. All the blood entering the liver is collected up and eventually  leaves the substance of the liver through three  great veins.

The liver has a major role in dealing with the nutrient products of food digestion. It deals with drugs and other toxins absorbed via the intestines. It is involved in recycling red blood cells by breaking these down and one of the by products of this process is bile which plays a role in the digestion of fats. It produces essential proteins, clotting factors for the blood and it regulates cholesterol metabolism.

The liver is metabolically very active but despite this it is a remarkably resilient organ and the human body can withstand the loss of up to two thirds of the normal liver without the development of liver insufficiency.

  • The liver is the largest internal organ. It filters the blood from the digestive system, metabolising toxins and monitoring nutrients such as glucose and cholesterol.
  • Liver disease often develops over years, without obvious symptoms. Many people are diagnosed with liver disease after abnormalities are detected during routine blood tests.
  • Cirrhosis occurs when the liver is inflamed and scar tissue forms. It is irreversible; thus prevention of liver disease is the ideal. Cirrhosis can be caused by alcohol consumption, hepatitis, right-sided heart failure, and other conditions.
  • Antioxidants, which neutralise the toxins processed by the liver, are an important element in liver health.
  • Treatment of liver disease is limited because many drugs are metabolised by the liver; thus only a few drugs, including corticosteroids, which have significant side effects, are used routinely to treat liver disease.

Liver detoxification

The liver has three main detoxification pathways:

  1. Filtering of the blood to remove large toxins;
  2. breaking down enzymatically unwanted chemicals, which usually occurs in two steps: Phase I modifies the chemicals to make them an easier target for the Phase II enzyme systems;
  3. synthesising and secreting bile for excretion of fat-soluble toxins and cholesterol.

Filtering of the blood is one of the liver’s primary functions. Approximately two quarts of blood pass through the liver every minute to be detoxified. This is critical, as the blood is loaded with bacteria, endotoxins and antigen-antibody complexes and various other toxic substances from the intestines. A healthy liver clears almost 100% of the bacteria and toxins from the blood before it joins the general circulation.

The liver’s second main role in detoxification involves an enzymatic process in two steps for the neutralisation of unwanted chemical compounds, such as drugs, pesticides and enterotoxins from the intestines. Even normal body compounds such as hormones get eliminated this way. Phase I enzymes directly neutralise some of these chemicals, but many others are converted to intermediate forms that are then processed by phase II enzymes. These intermediate forms are often much more chemically active and therefore more toxic than the original substance, so if the Phase II detoxification systems aren’t working adequately, these intermediates linger and cause damage.

Phase I detoxification involves a group of 50 to 100 enzymes called the cytochrome P450 system. These enzymes play a central role in the detoxification of both exogenous (such as drugs and pesticides) and endogenous (such as hormones) compounds and in the synthesis of steroid hormones and bile acids.

A side effect of this metabolic activity is the production of free radicals, which are highly reactive molecules that will bind to cellular components and cause damage. The most important antioxidant for neutralising these free radicals is glutathione, which is needed both for Phase I and Phase II. When exposure to high levels of toxin produce so many free radicals from Phase I detoxification that all the glutathione is used up, Phase II processes dependent on glutathione stop. This causes an imbalance between Phase I and Phase II activity, which results in severe toxic reactions, due to buildup of toxic intermediate forms.

Phase II detoxification involves conjugation, which means that a protective compound becomes bound to the toxin. Besides glutathione conjugation there are essentially six other pathways: amino acid conjugation, methylation, sulphation, sulphoxidation, acetylation and glucuronidation. These enzyme systems need nutrients and metabolic energy in order to work. If the liver cells are not functioning properly, phase II detoxification slows down and increases the toxic load by allowing the buildup of toxic intermediates.

The third major role of the liver is synthesis and secretion of bile. The liver manufactures approximately one quart of bile every day, which serves as a carrier for toxic substances to be effectively eliminated from the body. In addition, the bile emulsifies fats and fat-soluble vitamins in the intestine, improving their absorption. When the excretion of bile is inhibited (cholestasis), toxins stay in the liver longer with damaging effects. Bile acids are also understood to be important signalling molecules for other essential events in human physiology.

Cholestasis has several causes, one of which is obstruction of the bile ducts by the presence of gallstones. Bile flow can also be impaired within the liver itself. By far the most important cause of cholestasis and impaired liver function is the consumption of alcohol. Other common causes are viral hepatitis and side effects from various drugs, particularly steroidal hormones including oestrogen and oral contraceptives.

These conditions often cause alterations of liver function tests indicating cellular damage. In the initial stages of liver dysfunction, however, standard tests (serum bilirubin, alkaline phosphatase, SGOT, LDH, GGTP, etc.) are usually not sensitive enough to be of value. The measurement of serum bile acids, on the other hand, has proven to be a safe and sensitive test to determine the functional capacity of the liver.

Symptoms that may indicate reduced liver function are general malaise, fatigue and digestive disturbances including constipation, allergies and chemical sensitivities. Generalised pruritus, and nausea and vomiting during pregnancy can also be a result of impaired hepatofunction.

Both groups of enzymes in Phase I and Phase II are reliant on vitamins, minerals or amino acids to function, hence the importance of adequate nutrition to support liver detoxification.

Related products available at Nutri-Link:

Code Product description Type Size Supplier
5100 B6 Phosphate Tabs 100 BRC
1210 Beta Plus™ Tabs 90 BRC
1209 Beta Plus™ Tabs 180 BRC
1215 Beta-TCP™ Tabs 90 BRC
1216 Beta-TCP™ Tabs 180 BRC
71910 BifidoBiotics Caps 60 ARG
1199 Bio-6-Plus™ (Pancreatic Enzymes) Tabs 90 BRC
1282 Bio-BifidoBacT Pwdr 75g BRC
SP650 BodyBio PC (900 mg./cap) Caps 300 BB
SP600 BodyBio PC (900 mg./cap) Caps 100 BB
SP550 BodyBio PC Liquid (3000 mg./tsp) Liq 474ml BB
SP500 BodyBio PC Liquid (3000 mg./tsp) Liq 237ml BB
3006 Cytozyme-LV™ Tabs 60 BRC
74230 Fast & Be Clear (VAT Exempt) Pwdr 900g ARG
72460 GI Flora Caps 90 ARG
5101 Ginkgo Biloba Tabs 60 BRC
70140 Gluta-Ascorbs (Glutathione) Caps 60 ARG
5203 GSH-Plus™ Caps 60 BRC
76100 L-Ornithine-L-Aspartate Pwdr 100g ARG
73390 Lactobacillus GG Culturelle® Caps 30 ARG
72780 Lactobacillus plantarum/rhamnosus/salivarius Caps 100 ARG
70470 Liver Beef Natural Glandular Caps 100 ARG
70470 Liver Powder Beef Pwdr 200g ARG
LM209 Liquid Iodine- No. 9 Liq 60ml BB
LM403 Liquid Magnesium – No. 3 Liq 120ml BB
LM203 Liquid Magnesium – No. 3 Liq 60ml BB
70470 Liver Organic Glandular, 500mg Caps 125 ARG
74940 Liver Saver Tabs 120 ARG
75990 MicroChitosan Caps 60 ARG
1707 Mg-Zyme™ (Magnesium) Tabs 100 BRC
5205 NAC Caps 120 BRC
6401 NutriClear® Berry Pwdr 836g BRC
6400 NutriClear® (VAT Exempt) Pwdr 836g BRC
70850 Ox Bile Caps 100 ARG
72240 Phosphatidyl Choline, 385mg Soft Gel 100 ARG
1410 Phosphatidylcholine Caps 100 BRC
56500 ProBerry-Amla™ Pwdr 265g ARG
56590 ProBerry-Amla™ Stick Packs Pkts 15 ARG
70320 Solution of Magnesium Liq 237ml ARG
71130 SymBiotics with FOS Powder Pwdr 140g ARG
72640 ThioDox® Glutathione Complex Tabs 90 ARG
6420 Whey Protein Isolate (VAT Exempt) Pwdr 454g BRC


  1. Melhem A, Stern M, Shibolet O, Israeli E, Ackerman Z, Pappo O, Hemed N, Rowe M, Ohana H, Zabrecky G, Cohen R, Ilan Y. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol. 2005 Sep;39(8):737-42. View Abstract
  2. Corrao G, Zambon A, Bagnardi V, Aricò S, Loguercio C, D’Amicis A Nutrient intakes, nutritional patterns and the risk of liver cirrhosis: an explorative case-control study. Eur J Epidemiol. 2004;19(9):861-9. View Abstract
  3. Yu, SY, Zhu, YJ ,Li, WG Protective role of selenium against hepatitis B virus and primary liver cancer in Qidong. Biol Trace Elem Res, Jan 1997; 56(1): 117-24. View Abstract
  4. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R; Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003 Jun;124(7):1792-801. View Abstract
  5. Zhao J et al. Significant inhibition by the flavonoid antioxidant silymarin against 12_Otetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and coclooxygenase 2 and interleukin-1 alpha expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor promotion. Mol Carcinog 1999;26:321-33. View Abstract
ˆ Back to top
We use cookies and similar tools across our websites to improve their performance and enhance your user experience. Learn more about our Cookies Policy and click I understand, to hide this message.